https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46760 Wed 30 Nov 2022 09:30:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45088 Wed 26 Oct 2022 12:23:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53640 Wed 13 Dec 2023 10:34:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34998 Wed 02 Mar 2022 14:29:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44965 Tue 25 Oct 2022 13:46:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47625 Tue 24 Jan 2023 14:02:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49602 Tue 23 May 2023 15:26:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53314 Tue 21 Nov 2023 12:37:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49445 Tue 16 May 2023 13:53:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46318 Tue 15 Nov 2022 11:45:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46280 Tue 15 Nov 2022 08:30:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35024 Thu 21 Oct 2021 12:46:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33588 Mycobacterium tuberculosis, Mtb) treatment involves multiple drug regimens for a prolonged period. However, the therapeutic benefit is often limited by poor patient compliance, subsequently leading to treatment failure and development of antibiotic resistance. Notably, oxidative stress is a crucial underlying factor that adversely influences the various treatment regimens in tuberculosis. Little information is available with advanced drug delivery systems that could be effectively utilized, in particular, for targeting the oxidative stress in tuberculosis. Thus, this presents an opportunity to review the utility of various available, controlled-release drug delivery systems (e.g., microspheres, liposomes, niosomes, solid lipid nanoparticles, dendrimers) that could be beneficial in tuberculosis treatments. This will help the biological and formulation scientists to pave a new path in formulating a treatment regimen for multi-drug resistant Mtb.]]> Thu 03 Feb 2022 12:21:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40893 Streptococcus pneumoniae, non-typeable Haemophilus influenzae, Mycobacterium tuberculosis, Aspergillus fumigatus, etc., have the ability to elicit pro-oxidant pathways in the respiratory tract. Also, these pathogens are equipped with enzymatic and non-enzymatic mechanisms to neutralize host-associated oxidative molecules that facilitate the persistence of these pathogens in the lungs. We will discuss the CRD/pathogen-triggered oxidative stress in the lungs. We will also discuss the microbial mechanisms that may further increase oxidative stress in patients with CRDs that potentially results in the heightened inflammatory response in the lungs. Finally, we will discuss the current treatment strategies to limit the oxidative response-associated lung pathologies.]]> Fri 22 Jul 2022 10:38:45 AEST ]]>